药物临床试验登记与信息公示平台数据显示,北京加科思新药研发有限公司的评价JAB - 26766单药治疗及与替雷利珠单抗联合治疗用于晚期实体瘤的安全性、耐受性、药代动力学以及初步抗肿瘤活性的多中心、开放性I/IIa期研究已启动。临床试验登记号为CTR20253537,首次公示信息日期为2025年9月19日。该药物剂型为片剂,规格有25mg和100mg,用法为口服,按方案规定每日固定剂量给药,用药时程...
Source Link药物临床试验登记与信息公示平台数据显示,北京加科思新药研发有限公司的评价JAB - 26766单药治疗及与替雷利珠单抗联合治疗用于晚期实体瘤的安全性、耐受性、药代动力学以及初步抗肿瘤活性的多中心、开放性I/IIa期研究已启动。临床试验登记号为CTR20253537,首次公示信息日期为2025年9月19日。该药物剂型为片剂,规格有25mg和100mg,用法为口服,按方案规定每日固定剂量给药,用药时程...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.